Mycophenolic acid metabolic and transport pathway (MPA-UGT-OATP Pathway)

The Mycophenolic acid (MPA) metabolic and transport pathway describes the complex pharmacokinetic processes governing the disposition of the immunosuppressant MPA. MPA is primarily metabolized by UDP-glucuronosyltransferases, specifically UGT1A9 in the liver and UGT1A8 in the gastrointestinal tract, into the inactive metabolite mycophenolic acid glucuronide (MPAG) (Source: PMID: 15536153). A significant feature of this pathway is enterohepatic recirculation, where MPAG is excreted into the bile via the Multidrug Resistance-associated Protein 2 (MRP2) and subsequently deconjugated by bacterial beta-glucuronidases in the colon back into MPA for reabsorption (Source: PMID: 21459980). Organic Anion Transporting Polypeptides, such as OATP1B1 and OATP1B3, are critical for the hepatic uptake of MPAG from the blood, further influencing systemic exposure (Source: PMID: 18503002). Understanding this pathway is vital for clinical management, as genetic polymorphisms in UGT enzymes or OATP transporters can lead to significant inter-individual variability in drug efficacy and toxicity. For instance, certain UGT1A9 variants are associated with altered clearance, while drugs like cyclosporine can inhibit the biliary excretion of MPAG, reducing the secondary MPA peak and overall exposure (Source: PMID: 15970795). This pathway is a primary focus for therapeutic drug monitoring and personalized medicine in transplant recipients to prevent organ rejection while minimizing adverse effects like leukopenia and gastrointestinal distress.

Other names

MPA pharmacokineticsMycophenolate mofetil metabolismUGT-mediated glucuronidation of MPAOATP-mediated transport of mycophenolic acidEnterohepatic circulation of MPA

Mycophenolic acid (MPA) acts as a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), specifically the type II isoform. This inhibition depletes intracellular guanosine nucleotides, which are essential for DNA synthesis in T and B lymphocytes, thereby inhibiting their proliferation (Source: PubChem CID 446596; PMID: 15970795). The UGT enzymes (primarily UGT1A9 and UGT1A8) convert MPA into its inactive phenolic glucuronide (MPAG), while OATP transporters (OATP1B1 and OATP1B3) facilitate the hepatic uptake of these metabolites, contributing to the drug's enterohepatic recirculation (Source: PMID: 18503002).